Displaying drugs 14326 - 14350 of 15157 in total
Phthalocyanine
Phthalocyanine is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Investigational
Setiptiline
Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Experimental
Matched Description: … Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic …
Fluoromisonidazole F-18
Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer).
Investigational
Matched Description: … Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and …
Fluorescin
Experimental
Propyphenazone
Experimental
Vactosertib
Vactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).
Investigational
CPD 923
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Investigational
Matched Description: … CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. …
Selatogrel
Selatogrel is under investigation in clinical trial NCT03814200 (A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects).
Investigational
Matched Description: … investigation in clinical trial NCT03814200 (A Study to Investigate the Effect of Rifampicin on the Uptake and …
JNJ-42165279
Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).
Investigational
Matched Description: … Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability …
NOP-1A
NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).
Investigational
Matched Description: … NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies …
V116517
V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)).
Investigational
Matched Description: … V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 …
Paltusotine
Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)).
Investigational
Matched Description: … Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and …
AC3056
AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.
Investigational
Matched Description: … It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials. …
TC-5231
TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder). TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine.
Investigational
KAI-1455
KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and hip replacement and may protect against renal injury associated with contrast media. Several studies...
Investigational
Matched Description: … hip replacement and may protect against renal injury associated with contrast media. ... may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and …
2-Phenethyl-2,3-Dihydro-Phthalazine-1,4-Dione
Experimental
PQ-10
Experimental
Displaying drugs 14326 - 14350 of 15157 in total